Skip to content

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

NOC4L: An Emerging Dual-Action Target for Cancer Prognosis and Immunotherapy.

NOC4L shows promise as a dual-action target, functioning both as a prognostic biomarker and as a potential immunotherapeutic target, and is associated with overall survival in 20 cancer types, suggesting its potential as an independent prognostic marker.

Hai Bai, Wan-Qing Xu, Guo-Zheng Wei et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.